For families caring for someone with Alzheimer’s disease or another form of dementia, memory loss is only part of the challenge. Agitation, anxiety, aggression, disrupted sleep, loss of appetite, and emotional distress can dramatically affect a patient’s daily comfort—and place an enormous burden on caregivers.
A growing body of research is examining whether cannabinoids, particularly combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC), might help manage some of these difficult symptoms.
The most exciting findings to date were announced in July 2026. A major U.S. randomized clinical trial found that a carefully formulated combination of CBD and THC significantly reduced agitation in people with late-stage dementia, with improvements appearing within just two weeks. (AAIC 2027)
These findings do not mean that CBD or THC cures dementia, reverses Alzheimer’s disease, or restores lost memory. Instead, researchers are investigating something that may be equally important for patients with advanced disease: whether cannabinoid therapy can help people feel calmer, sleep better, experience less distress and enjoy a better quality of daily life.
The Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol, or LiBBY, trial is particularly important because it was a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial—the type of research needed to determine whether a treatment actually works.
Researchers enrolled 120 people with Alzheimer’s disease or other forms of dementia who were hospice-eligible and experiencing significant agitation.
Participants received either placebo or a specially manufactured oral medication combining CBD with a relatively small amount of THC.
The results were striking.
After only two weeks, participants receiving CBD/THC had a 6.27-point greater reduction in agitation than those receiving placebo. By 12 weeks, the difference had grown to 8.23 points.
Clinicians also evaluated the participants’ overall behavioral improvement. At two weeks, 83.9% of patients receiving CBD/THC were rated as improved compared with 30.5% receiving placebo. At 12 weeks, 87.2% of treated patients had improved compared with 23.6% receiving placebo. (AAIC 2027)
Participants who continued treatment during an open-label extension appeared to maintain benefits through 24 weeks. Researchers also reported that people who switched from placebo to the CBD/THC treatment during the extension subsequently experienced reductions in agitation. (School of Medicine)
For families dealing with severe dementia, reducing agitation can translate into something very meaningful: fewer episodes of fear, pacing, aggression or emotional distress and potentially more peaceful interaction between the patient and those caring for them.
Researchers described the potential benefit in terms of comfort, dignity and quality of life near the end of life. (AAIC 2027)
There is one important qualification. As of August 2026, these are topline clinical-trial results presented at the Alzheimer’s Association International Conference, rather than a complete peer-reviewed journal publication. The findings are therefore highly encouraging, but further publication and confirmation are important.
Several studies conducted before LiBBY also found promising signals, although most involved much smaller groups.
2026 — Silva et al., American Journal of Geriatric Psychiatry. A systematic review and meta-analysis examined seven studies involving 221 participants, including six randomized trials. Cannabinoid-based treatments were associated with significantly lower agitation and neuropsychiatric symptom scores than placebo, with small-to-moderate effects. The researchers found no consistent evidence that cannabinoids improved cognition. Somnolence or sedation was the clearest safety concern. (PubMed)
2026 — Pan et al., CNS Drugs. This systematic review and meta-analysis included 10 randomized studies involving 328 people with dementia. Cannabinoids did not significantly improve total neuropsychiatric symptoms as a whole, but they did significantly reduce agitation. The benefit was particularly apparent in studies involving people with severe dementia. However, results varied considerably across studies, and the finding on agitation was no longer statistically significant after studies at high risk of bias were removed. Sedation was about twice as common with cannabinoids. (PubMed)
2025/2026 — Ravelli et al., Journal of Psychopharmacology. Researchers reviewed 10 studies involving 278 older adults with dementia. Overall, the studies suggested that cannabinoid treatments may help reduce agitation and nighttime disturbances, with generally acceptable tolerability. The authors emphasized that larger studies are still needed. (PubMed)
2025 — STAND Trial, United Kingdom. The STAND study tested nabiximols, a medication containing approximately a 1:1 combination of THC and CBD, in people with Alzheimer’s disease and significant agitation living in care homes. Twenty-nine participants were randomized. The study was primarily designed to determine whether a larger trial would be practical rather than prove effectiveness. Still, researchers found that treatment was feasible, adherence was excellent, and the cannabinoid combination was well tolerated, supporting a larger efficacy trial. (PubMed Central (PMC)
2023 — Timler et al., Australasian Journal on Ageing. Twenty-one residents with dementia participated in an 18-week randomized, double-blind crossover trial using a cannabinoid medicine with a 3:2 THC-to-CBD ratio. Agitation decreased at the end of cannabinoid treatment, and caregivers described improved relaxation and sleep in some participants. Importantly, the study did not find a statistically significant improvement in its formal quality-of-life measurement, illustrating why it is too early to claim that CBD/THC universally improves quality of life. (PubMed)
2023 — Palmieri and Vadalà, La Clinica Terapeutica. Thirty adults aged 65 to 90 with Alzheimer’s disease received a cannabis extract containing both THC and CBD for 12 weeks. Researchers reported improvements in agitation, apathy, irritability, sleep disturbances, and eating disturbances, along with reduced caregiver distress and aggressive behavior. However, this was an observational study without a placebo group, so the results should be considered preliminary rather than definitive. (PubMed)
2022 — Hermush et al., Frontiers in Medicine. In a randomized, double-blind, placebo-controlled trial involving 60 people with dementia, researchers tested a CBD-rich cannabis oil that also contained THC. After 16 weeks, 60% of patients receiving the cannabinoid treatment experienced at least a four-point improvement in agitation compared with 30% receiving placebo. Half of the treatment group achieved an improvement of at least eight points compared with 15% of the placebo group. (PubMed)
2022 — Pautex, Bianchi et al., Frontiers in Aging Neuroscience. Nineteen nursing-home residents with severe dementia received a standardized 1:2 THC-to-CBD preparation, averaging approximately 12.4 mg THC and 24.8 mg CBD daily after dose adjustment. Patients were followed for as long as 13 months. Researchers reported sustained improvements in behavioral and clinical measures, reduced use of some other medications, and easier daily caregiving. Because there was no placebo comparison group, the study cannot establish that cannabis caused those improvements, but it provided valuable longer-term safety and feasibility data. (Frontiers)
CBD and THC interact with the body’s endocannabinoid system, a signaling network involved in mood, sleep, appetite, pain perception, stress responses and other neurological processes.
THC directly influences cannabinoid receptors in the brain and can produce relaxation, appetite stimulation, and changes in perception. At higher doses, however, THC can also produce confusion, anxiety, sedation and impairment.
CBD is not intoxicating in the same way. It interacts with numerous neurological signaling systems and may modify some of THC’s effects.
This has led researchers to investigate specific CBD-to-THC ratios rather than simply giving patients cannabis.
The LiBBY trial is a particularly good example. Researchers did not give patients ordinary dispensary marijuana. They used a precisely manufactured pharmaceutical formulation containing much more CBD than THC and administered it under medical supervision. Georgetown researchers specifically warned that commercially available cannabis products should not be assumed to produce the same effects as the medication tested in the trial. (School of Medicine)
One of the most important lessons emerging from this research is that improving dementia care does not necessarily mean reversing memory loss.
In advanced dementia, quality of life may depend heavily on whether a person is comfortable or frightened, sleeping or restless, calm or agitated, eating adequately, and able to enjoy moments of connection with family members.
Agitation can include pacing, repetitive movements, shouting, moaning, hostility and physical aggression. In people who can no longer communicate effectively, these behaviors may be expressions of fear, discomfort or unmet needs. (AAIC 2027)
If cannabinoid therapy can reduce some of those behaviors without causing excessive sedation, it could potentially make daily life more comfortable for patients while simultaneously reducing stress for caregivers.
That is why the LiBBY findings are so significant. The treatment did not cure dementia. It appeared to make some of the most difficult aspects of advanced dementia considerably easier to manage.
There is currently no convincing human evidence that cannabis, THC or CBD reverses Alzheimer’s disease, restores lost brain function or prevents dementia from progressing. The newer studies primarily concern behavioral symptoms—especially agitation—rather than the underlying neurodegenerative disease. (Alzheimer’s Society)
The most accurate conclusion is therefore that CBD/THC combinations may improve important symptoms that contribute to quality of life, with the evidence for reducing agitation becoming substantially stronger.
CBD can interact with prescription medications and affect how the body metabolizes certain drugs. The FDA specifically cautions that taking CBD along with other medications can increase or decrease their effects and potentially increase adverse reactions. (U.S. Food and Drug Administration) It’s important to consult a physician knowledgeable about interactions between prescription drugs and cannabis. That is especially relevant in dementia because older patients frequently take multiple medications.
Research into cannabinoids and dementia has changed significantly during the past several years.
Earlier studies were generally small and produced mixed results. Today, larger randomized studies—most notably the 2026 LiBBY trial—are beginning to provide stronger evidence that carefully designed combinations of CBD and THC may help reduce severe agitation and improve comfort in some people with advanced dementia.
The latest research does not establish cannabis as a cure for Alzheimer’s disease. But it raises an important possibility: for some dementia patients, particularly those struggling with severe agitation, carefully supervised cannabinoid treatment might eventually provide a calmer and more comfortable daily life.
The next step will be larger clinical trials, peer-reviewed publication of the LiBBY results, studies comparing different THC-to-CBD ratios, and research designed specifically to measure sleep, caregiver burden and quality of life over longer periods.
For now, families interested in cannabinoid treatment for a person with dementia should discuss it with a physician familiar with the patient’s medications, medical conditions, and level of cognitive impairment rather than attempting to reproduce clinical-trial treatments with commercially available CBD or cannabis products. The physicians and healing specialists at The Healing Clinics are ready to help. Click the button below to get started or call (318) 227-4088 for more information.
This blog post was outlined and drafted with the help of AI tools, then reviewed, edited, and fact-checked by a human author.
